Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNKS | O95271 | 3/20 | 0.52 |
| ▸ | TLR9 | Q9NR96 | 4/20 | 0.49 |
| ▸ | TLR8 | Q9NR97 | 4/20 | 0.49 |
| ▸ | TLR7 | Q9NYK1 | 4/20 | 0.49 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.47 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.47 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.46 |
| ▸ | FYN | P06241 | 2/20 | 0.46 |
| ▸ | PLK4 | O00444 | 1/20 | 0.44 |
| ▸ | FLT3 | P36888 | 1/20 | 0.44 |
| ▸ | MGLL | Q99685 | 3/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | TDO2 | P48775 | 1/20 | 0.41 |
| ▸ | IL2 | P60568 | 1/20 | 0.41 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.41 |
| ▸ | RIOK2 | Q9BVS4 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13429268 | 0.90 | TLR9 (0.47) | TLR9TLR8TLR7MGLLIL2 | |
| SCHEMBL13429202 | 0.89 | TLR9 (0.45) | TNKSTLR9TLR8TLR7ALK | |
| SCHEMBL13429235 | 0.89 | CNR2 (0.51) | TLR8TLR7MGLLTDO2MAP4K1 | |
| SCHEMBL13429243 | 0.85 | CKS1B (0.48) | TLR8TLR7MGLL | |
| SCHEMBL13429057 | 0.82 | ALK (0.48) | TNKSTLR9TLR8TLR7ALK | |
| SCHEMBL3225576 | 0.82 | KIF11 (0.47) | TLR9TLR8TLR7 | |
| SCHEMBL13429354 | 0.80 | GRIN2D (0.41) | TLR8TLR7 | |
| SCHEMBL3209675 | 0.80 | MAP4K4 (0.43) | TLR9TLR8TLR7FYNATM | |
| SCHEMBL13429163 | 0.80 | AXL (0.41) | PRMT5WDR77FYNFLT3 | |
| SCHEMBL13429309 | 0.78 | TLR9 (0.44) | TLR9TLR8TLR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100068204-A1 | 4-ARYLOXYQUINOLIN-2(1H)-ONES AS MTOR KINASE AND PI3 KINASE INHIBITORS, FOR USE AS ANTI-CANCER AGENTS | WYETH (US) | 2010-03-18 | — | — | US | disclosed |
| US-20100068204-A1 | 4-ARYLOXYQUINOLIN-2(1H)-ONES AS MTOR KINASE AND PI3 KINASE INHIBITORS, FOR USE AS ANTI-CANCER AGENTS | WYETH (US) | 2010-03-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100068204-A1 | 4-ARYLOXYQUINOLIN-2(1H)-ONES AS MTOR KINASE AND PI3 KINASE INHIBITORS, FOR USE AS ANTI-CANCER AGENTS | MTOR, RICTOR, PIK3CA | TNKS 506/4885TLR9 1426/4885TLR8 3578/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.